Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. commercializes ophthalmic disease management products in North America, with a portfolio used in dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions and retina diseases. Its recurring news includes financial results and stockholder letters, commercial product updates for therapies such as VEVYE, ILEVRO, IOPIDINE and TRIESENCE, and distribution arrangements supporting U.S. product availability.
Company updates also cover reimbursement and regulatory developments, scientific presentations in ophthalmology, clinical development for label expansion, product launches and capital actions such as senior unsecured notes. Harrow reports through branded ophthalmic pharmaceuticals and ImprimisRx, reflecting both commercial products and specialty ophthalmic medication operations.
Harrow (Nasdaq: HROW) will report second quarter 2026 financial results for the period ended June 30, 2026, after the market close on Monday, August 10, 2026. The company will post its Letter to Stockholders and host a conference call and webcast at 8:00 a.m. ET on Tuesday, August 11, 2026, with replay available on its investor website for one year.
Harrow (Nasdaq: HROW) and Samsung Bioepis reported interim results from a large, real-world Phase 4 post-marketing surveillance study of SB11 (BYOOVIZ / AMELIVU), a biosimilar to Lucentis, conducted in the Republic of Korea and presented at ASRS 2026.
The open-label, prospective, multicenter study (May 2022–May 2026) followed patients for up to 24 weeks after first dose. Interim data covered 298 patients (182 treatment‑naïve, 116 switched from other anti‑VEGF therapies). Mean best‑corrected visual acuity (BCVA) improved by -0.10 (SD 0.29) in treatment‑naïve and -0.03 (SD 0.24) in switched patients (P=0.0239). Mean central subfield thickness (CST) changed by -95 (SD 125) µm and -53 (SD 108) µm, respectively (P=0.0168). Disease duration was significantly associated with BCVA (P=0.0003) and CST (P=0.001) outcomes, and no new safety concerns were identified, which Samsung Bioepis and Harrow said supports confidence in SB11’s real‑world use.
Harrow (Nasdaq: HROW) reported three study presentations on IHEEZO and BYOOVIZ at the ASRS 2026 Annual Meeting, adding to clinical and real‑world evidence for its retina portfolio. According to Harrow, an interim, investigator‑initiated randomized study in 150 intravitreal injection patients comparing IHEEZO with subconjunctival lidocaine showed early trends toward less post‑procedure pain, improved post‑injection experience, and fewer ocular symptoms over 24 hours in the IHEEZO group.
Harrow continues enrolling QUELL, a prospective, randomized, multicenter IHEEZO trial in about 236 subjects under an active IND, with topline data expected in Q4 2026. A separate retrospective real‑world analysis of nearly 20,000 injections found no evidence that IHEEZO’s low‑viscosity gel formulation increased endophthalmitis risk versus a legacy tetracaine/povidone‑iodine regimen. Samsung Bioepis also presented interim findings from a large post‑marketing BYOOVIZ surveillance study, with full results being announced jointly with Harrow.
Harrow (Nasdaq:HROW) and Samsung Bioepis announced the US relaunch of BYOOVIZ (ranibizumab-nuna), an interchangeable biosimilar to Lucentis, under a commercialization partnership. Samsung Bioepis handles development, regulatory registration, and manufacturing, while Harrow leads US commercialization of both BYOOVIZ and OPUVIZ (aflibercept-yszy).
BYOOVIZ is FDA-approved and interchangeable for treating wet AMD, macular edema following RVO, and mCNV. OPUVIZ, interchangeable to Eylea, is indicated for wet AMD, RVO-related macular edema, DME, and DR.
Harrow (Nasdaq:HROW) announced the U.S. commercial launch of BYOOVIZ (ranibizumab-nuna), an FDA-approved, interchangeable biosimilar referencing LUCENTIS for Wet AMD, RVO-related macular edema, and mCNV.
Harrow holds exclusive U.S. commercialization rights to BYOOVIZ and OPUVIZ, expanding its retina portfolio alongside IHEEZO and TRIESENCE in a roughly $9 billion U.S. anti-VEGF market.
Harrow (Nasdaq:HROW) announced the re-launch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, indicated for all forms of vernal keratoconjunctivitis (VKC) in children and adults.
The topical calcineurin inhibitor targets underlying VKC inflammation, showed statistically significant trial results, and is backed by physician education, access, and affordability programs to improve long-term pediatric eyecare.
Harrow (Nasdaq:HROW) announced that management will present at William Blair’s 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL.
The presentation will be webcast live on Harrow’s website, with a replay available for about 90 days.
Harrow (Nasdaq:HROW) reported first quarter 2026 revenue of $44.2 million, reduced by an approximate $8 million non-recurring VEVYE gross-to-net adjustment. VEVYE prescriptions hit records and surpassed XIIDRA with about 14% dry eye market share.
Unit demand for IHEEZO rose 18% year-over-year, and TRIESENCE demand increased 136%. Net loss was $27.6 million, or $0.74 per share. Full-year 2026 revenue guidance of $350–$365 million and second-quarter revenue outlook of $71–$81 million were reiterated. Cash and cash equivalents totaled $94.6 million as of March 31, 2026.
Harrow (Nasdaq: HROW) will report first quarter 2026 financial results for the period ended March 31, 2026, on Monday, May 11, 2026 after market close. The company will post a Letter to Stockholders on its Investors page at harrow.com.
Harrow will host a live webcast and conference call at 8:00 a.m. ET on Tuesday, May 12, 2026 to discuss results and provide a business update. Telephone participants must register in advance to receive a unique dial-in number and PIN. A replay of the webcast will be available on the company website for one year.
Harrow (Nasdaq: HROW) announced that IOPIDINE 1% (apraclonidine) received a permanent J-Code J2374, enabling in-office reimbursement effective July 1, 2026. The designation removes a practical barrier to routine office use and is expected to support broader adoption for prophylactic IOP management during ophthalmic laser procedures.
IOPIDINE 1% has shown a reduction in severe post-procedure IOP spikes from ~23% to ~2% (~91% relative reduction). The company highlights a large addressable base—>4 million glaucoma patients and >1.5 million annual ophthalmic laser procedures in the U.S.